• Created and implemented high quality clinical plans and data analysis strategies that apply appropriate enabling technologies, models and surrogate markers. • Defined the clinical activities needed to meet the requirements for Commit to Medicine Development. • Partnered with non-clinical scientists to ensure optimal preclinical support, and the use of translational disease and target PD markers in experimental medicine and Phase I/II clinical studies.

• Led matrix partners in defining the clinical activities that will meet the requirements for medicine development milestones. • Led clinical pharmacology matrix teams in the delivery of study objectives from study concept to study report including First Time in Human through Proof of ConceptDeveloped clinical study protocols and associated documentation (e.g., ICF, procedure manuals, study report). Coordinated scientific and technical contributions of relevant disciplines into study documentation. Managed clinical study operations for single and multi-center (2-25) studies. • Led global clinical projects and studies in multiple therapeutic areas Musculoskeletal, Antibiotic, Anti-inflammatory, Biopharmaceutical, Gastrointestinal, Cardiovascular• Prepared INDs, CTNs, CTAs, IMPDs and research ethics applications

Team leader of CNS disease group. Created in vivo screening platform to identify the pharmacodynamic and whole organ system effects of novel investigational compounds. Platform was also used to identify alternate therapeutic indications (repurpose) for failed candidate molecules.

Postdoctoral fellowship research focused on using G-protein coupled receptor knockout mice and in vivo models of anxiety, depression, epilepsy, pain, and cognition to validate targets of pharmaceutical interest.

Graduate research aimed at differentiating NMDA subunit selective antagonists activities in epilepsy models and whole-cell patch clamp.